Display options
Cite
Khoonsari H, Oghazian MB, Kargar M, et al. Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder. Iran J Psychiatry Behav Sci. 2015;9(2):e230doi: 10.17795/ijpbs230.
Khoonsari, H., Oghazian, M. B., Kargar, M., Moin, M., Khalili, H., Alimadadi, A., Torkamandi, H., & Ghaeli, P. (2015). Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder. Iranian journal of psychiatry and behavioral sciences, 9(2), e230. https://doi.org/10.17795/ijpbs230
Khoonsari, Hasan, et al. "Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder." Iranian journal of psychiatry and behavioral sciences vol. 9,2 (2015): e230. doi: https://doi.org/10.17795/ijpbs230
Khoonsari H, Oghazian MB, Kargar M, Moin M, Khalili H, Alimadadi A, Torkamandi H, Ghaeli P. Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder. Iran J Psychiatry Behav Sci. 2015 Jun;9(2):e230. doi: 10.17795/ijpbs230. Epub 2015 Jun 23. PMID: 26288644; PMCID: PMC4539397.
Copy Download .nbib Format: NLM
Share it on

Iran J Psychiatry Behav Sci. 2015 Jun;9(2):e230. doi: 10.17795/ijpbs230. Epub 2015 Jun 23.

Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder.

Iranian journal of psychiatry and behavioral sciences

Hasan Khoonsari, Mohammad Bagher Oghazian, Mona Kargar, Mahdiyeh Moin, Hossein Khalili, Abbas Alimadadi, Hassan Torkamandi, Padideh Ghaeli

Affiliations

  1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran.
  2. Research Center for Rational Use of Drugs, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran.
  3. Department of Psychiatry, Roozbeh Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran.
  4. University of Applied Science and Technology, Tehran, IR Iran.
  5. Pharmaceutical Care Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IR Iran.
  6. Psychiatry and Psychology Research Center, Faculty of Pharmacy, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IR Iran.

PMID: 26288644 PMCID: PMC4539397 DOI: 10.17795/ijpbs230

Abstract

BACKGROUND: Patients with mixed anxiety-depressive disorder (MADD) suffer both anxiety and depression. Antidepressants, especially, selective serotonin reuptake inhibitors are among agents of choice for treating this condition.

OBJECTIVES: This study compared the efficacy of Cipram® with its generic, citalopram.

PATIENTS AND METHODS: Forty adult outpatients (between 18 to 55 years of age) with a diagnosis of MADD who met the trial criteria, entered this double-blind, randomized study. Subjects were assigned to receive either generic citalopram or Cipram® for 8 weeks. Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) were utilized to assess depression and anxiety at baseline, weeks 4 and 8 of the study. Statistical analysis was performed using SPSS 14.0.

RESULTS: Twenty patients received citalopram (mean dosages of 22 mg/day during the first 4 weeks and 33 mg/day during weeks 4 to 8) and 20 received Cipram® (mean dosages of 22 mg/day during the first 4 weeks and 29 mg/day during weeks 4 to 8). Both treatments were noted to be effective in improving the symptoms of MADD at weeks 4 and 8. The mean differences of HAM-D and HAM-A between Citalopram and Cipram® groups were significantly different at the end of week 4 (HAM-D: P = 0.038, HAM-A: P = 0.025), but not at the end of week 8 (HAM-D: P = 0.239, HAM-A: P = 0.204). Both medications were tolerated well by the patients.

CONCLUSIONS: This study suggests that the efficacy of citalopram is similar to that of Cipram® in the treatment of MADD after 8 weeks. Meanwhile, Cipram® may reduce depression and anxiety quicker than its generic, citalopram.

Keywords: Anxiety; Citalopram; Depressive Disorder; Serotonin Uptake Inhibitors

References

  1. J Affect Disord. 2000 Jul;59(1):67-9 - PubMed
  2. Clin Ther. 2001 Oct;23(10):1720-31 - PubMed
  3. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):85-102 - PubMed
  4. Health Policy. 2010 May;95(2-3):229-35 - PubMed
  5. J Affect Disord. 2010 Feb;121(1-2):180-3 - PubMed
  6. Clin Ther. 2003 Nov;25(11):2875-90 - PubMed
  7. Dig Liver Dis. 2006 Aug;38(8):554-9 - PubMed
  8. Psychiatry Res. 2000 Apr 24;94(1):59-66 - PubMed
  9. Epilepsy Behav. 2004 Dec;5(6):995-8 - PubMed
  10. Health Policy. 2003 Sep;65(3):269-75 - PubMed
  11. Parkinsonism Relat Disord. 2011 Jun;17(5):308-12 - PubMed
  12. Croat Med J. 2009 Oct;50(5):440-8 - PubMed
  13. Res Social Adm Pharm. 2008 Sep;4(3):244-57 - PubMed
  14. Psychiatry Res. 2010 Apr 30;176(2-3):197-201 - PubMed
  15. J Affect Disord. 2004 Aug;81(2):185-6 - PubMed
  16. Ann Intern Med. 2008 Nov 18;149(10):734-50 - PubMed
  17. Epilepsy Res. 2011 Jun;95(1-2):158-67 - PubMed

Publication Types